DBVTDBV Technologies S.A.

Nasdaq dbv-technologies.com


$ 0.81 $ -0.05 (-5.53 %)    

Friday, 28-Jun-2024 15:56:19 EDT
QQQ $ 479.98 $ -2.50 (-0.52 %)
DIA $ 391.11 $ -0.43 (-0.11 %)
SPY $ 544.70 $ -2.15 (-0.39 %)
TLT $ 91.77 $ -1.74 (-1.86 %)
GLD $ 215.03 $ 0.02 (0.01 %)
$ 0.801
$ 0.81
$ 0.79 x 1,200
$ 0.00 x 0
$ 0.81 - $ 0.81
$ 0.78 - $ 4.04
97,646
na
38.52M
$ 1.10
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 03-07-2024 12-31-2023 10-K
3 10-31-2023 09-30-2023 10-Q
4 07-31-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 03-02-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-01-2022 06-30-2022 10-Q
9 05-02-2022 03-31-2022 10-Q
10 03-09-2022 12-31-2021 10-K
11 10-26-2021 09-30-2021 10-Q
12 08-02-2021 06-30-2021 10-Q
13 05-05-2021 03-31-2021 10-Q
14 03-17-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 dbv-technologies-announces-plan-to-implement-ads-ratio-change-from-1-ads-to-12-of-a-ordinary-share-to-1-ads-to-1-ordinary-share-anticipates-that-the-ads-ratio-change-will-be-effective-on-or-about-june-7th-2024

DBV Technologies, a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunolo...

 dbv-technologies-announces-plan-to-implement-ads-ratio-change-from-the-current-ads-ratio-of-1-ads-to-12-of-one-1-ordinary-share-to-a-new-ads-ratio-of-one-1-ads-to-1-ordinary-share

DBV Technologies Announces Plan to Implement ADS Ratio ChangeDBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stoc...

 hc-wainwright--co-maintains-buy-on-dbv-technologies-lowers-price-target-to-5

HC Wainwright & Co. analyst Andrew Fein maintains DBV Technologies (NASDAQ:DBVT) with a Buy and lowers the price target ...

 dbv-technologies-q1-eps-028-beats-021-estimate-sales-140m-miss-227m-estimate

DBV Technologies (NASDAQ:DBVT) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $(0....

 dbv-technologies-q4-2023-gaap-eps-0060-sales-8875m-beat-412000k-estimate

DBV Technologies (NASDAQ:DBVT) reported quarterly losses of $(0.060) per share. The company reported quarterly sales of $8.875...

 earnings-scheduled-for-march-7-2024

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on rev...

 hc-wainwright--co-reiterates-buy-on-dbv-technologies-maintains-10-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates DBV Technologies (NASDAQ:DBVT) with a Buy and maintains $10 price tar...

 dbv-technologies-and-2-other-stocks-under-2-insiders-are-buying

The Dow Jones index closed higher by around 50 points on Thursday. When insiders purchase or sell shares, it indicates their co...

 top-5-health-care-stocks-that-could-blast-off-in-december

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

 hc-wainwright--co-reiterates-buy-on-dbv-technologies-maintains-10-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates DBV Technologies (NASDAQ:DBVT) with a Buy and maintains $10 price tar...

 dbv-technologies-announces-2-year-results-from-ongoing-phase-3-open-label-extension-to-the-epitope-trial-of-viaskin-peanut-in-toddlers

DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ P...

 goldman-sachs-maintains-sell-on-dbv-technologies-lowers-price-target-to-1

Goldman Sachs maintains DBV Technologies (NASDAQ:DBVT) with a Sell and lowers the price target from $1.3 to $1.

 why-plus-therapeutics-shares-are-trading-higher-by-over-11-here-are-20-stocks-moving-premarket

Gainers